Skip to Content
Merck
  • Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

The journals of gerontology. Series A, Biological sciences and medical sciences (2014-08-20)
Maren S Fragala, Thuy-Tien L Dam, Vanessa Barber, James O Judge, Stephanie A Studenski, Peggy M Cawthon, Robert R McLean, Tamara B Harris, Luigi Ferrucci, Jack M Guralnik, Douglas P Kiel, Stephen B Kritchevsky, Michelle D Shardell, Maria T Vassileva, Anne M Kenny
ABSTRACT

The Foundation for the National Institutes of Health Sarcopenia Project developed data-driven cut-points for clinically meaningful weakness and low lean body mass. This analysis describes strength and function response to interventions based on these classifications. In data from four intervention studies, 378 postmenopausal women with baseline and 6-month data were evaluated for change in grip strength, appendicular lean mass corrected for body mass index, leg strength and power, and short physical performance battery (SPPB). Clinical interventions included hormones, exercise, and nutritional supplementation. Differences in outcomes were evaluated between (i) those with and without weakness and (ii) those with weakness and low lean mass or with one but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) and by treatment assignment. The women (72±7 years; body mass index of 26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with weakness increased grip strength, lost less leg power, and gained SPPB score (p < .05) compared with nonweak participants. Stratified analyses were similar for grip strength and SPPB. With lean mass in the analysis, individuals with weakness had larger gains in grip strength and SPPB scores regardless of low lean mass (p < .01). Older women with clinically meaningful muscle weakness increased grip strength and SPPB, regardless of the presence of low lean mass following treatment with interventions for frailty. Thus, results suggest that muscle weakness, as defined by the Foundation for the National Institutes of Health Sarcopenia Project, appears to be a treatable symptom.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
β-Estradiol, BioReagent, powder, suitable for cell culture
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
β-Estradiol, powder, γ-irradiated, suitable for cell culture
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
trans-Dehydroandrosterone, ≥99%
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
β-Estradiol, analytical standard
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Supelco
Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
Calcium citrate tetrahydrate, 99%
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
β-Estradiol, ≥98%
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Sigma-Aldrich
Estradiol, meets USP testing specifications
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
USP
Estradiol, United States Pharmacopeia (USP) Reference Standard
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Estradiol hemihydrate, European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Supelco
Dehydroepiandrosterone (DHEA) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00
Supelco
17β-Estradiol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
100 μL
Usually ships in 1 week. (Orders outside of US and Europe, please allow an additional 1-2 weeks for delivery)
US$598.00